Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights
First written in FY2017-Q3. 25 of 36 entries say "Advanced", first in FY2017. Latest entry: 2026-10-20.
1 other company's latest entry also says "Achieved".
- FY2026AdvancedAnnual report
「Of the ¥372 million in funds to be raised through the issuance of these common shares by the first third-party allotment, estimated net proceeds of ¥367 million are expected to be allocated to ¥300 million for clinical trials and preparation for the marketing authorization application for the TIL therapy project, and ¥67 million for working capital.」
The company decided on a share and Stock Acquisition Rights issuance program with CVI Investments, Inc. as the intended allottee, specifying plans to raise funds through the first third-party allotment for TIL therapy clinical trials, preparation for the marketing authorization application and working capital. - FY2025AchievedAnnual report
「Number of Stock Acquisition Rights acquired and cancelled: 11,343」
With respect to the Series 16 Stock Acquisition Rights, the remaining 11,343 rights were acquired and cancelled on 27 January 2025, leaving 0 rights outstanding. Funds raised through exercises during FY2025 amounted to ¥680 million, bringing cumulative funds raised to ¥1,219 million, and financing through these Stock Acquisition Rights ended. - FY2025-H1AdvancedAnnual report
「Funds generated from financing activities during the current interim consolidated accounting period amounted to ¥680 million (no change in the same period of the previous year). This was attributable to ¥680 million in proceeds from the issuance of shares through exercise of the Stock Acquisition Rights.」
Exercise of the Stock Acquisition Rights raised ¥680 million during the current interim consolidated accounting period. The number exercised was 53,183, the number of shares delivered was 5,318,300, and cumulative funds raised reached ¥1,219 million. - FY2024AdvancedAnnual report
「Funds generated from financing activities during the current consolidated fiscal year amounted to ¥544 million (¥482 million in the previous fiscal year). This was mainly attributable to ¥538 million in proceeds from the issuance of the Stock Acquisition Rights and from the issuance of shares through exercise of the Stock Acquisition Rights.」
Exercise of the Series 16 Stock Acquisition Rights resulted in the issuance of 3,547,400 shares and raised ¥538 million. The company also indicated plans to allocate the previously unfunded ¥1,990 million to the introduction of new pipelines and clinical trial expenses. - FY2024-Q3AdvancedAnnual report
「The funds expected to be raised through the issuance and exercise of the Series 16 Stock Acquisition Rights will be allocated to working capital from January 2024 onward. Of the ¥1,990 million that could not be raised previously, the company plans once again to allocate funds to the introduction of new pipelines and clinical trial expenses.」
The company specified plans to issue the Series 16 Stock Acquisition Rights and allocate the previously unfunded ¥1,990 million to the introduction of new pipelines and clinical trial expenses, while allocating funds raised from January 2024 onward to working capital. - FY2023Finalization of financing results and acquisition and cancellation of the Stock Acquisition RightsAnnual report
「Number of the relevant stock acquisition rights with exercise price adjustment provisions exercised during the period (units): 26,833 Number of shares delivered in connection with exercises during the period (shares): 2,683,300 Funds raised through exercises during the period (¥ million): 564 Cumulative funds raised through the relevant stock acquisition rights with exercise price adjustment provisions as of the end of the period (¥ million) 2,929」
With respect to the Series 15 Stock Acquisition Rights, 2,683,300 shares were issued and ¥564 million was raised in FY2023, bringing cumulative funds raised to ¥2,929 million. The remaining 15,107 rights were acquired and cancelled on 19 October 2022, leaving 0 rights outstanding. - FY2023-Q3Update on the increase in capital through exercise of the Stock Acquisition RightsAnnual report
「Through the issuance of new shares upon exercise of the Stock Acquisition Rights, the company’s share capital and capital surplus each increased by ¥284.236 million during the first nine months of the current consolidated fiscal year.」
The issuance of new shares upon exercise of the Stock Acquisition Rights increased share capital and capital surplus by ¥284.236 million each during the first nine months of the current consolidated fiscal year. - FY2023-Q2SoftenedAnnual report
「Following the issuance of these Stock Acquisition Rights, the company’s share price remained at a low level due to the business environment surrounding the company and stock market conditions. As the share price is currently below the minimum exercise price of ¥206, it is considered difficult to expect the allottee to exercise the Stock Acquisition Rights. In addition, although the planned funding amount at the time of issuance was ¥5,390 million, the company had raised ¥2,929 million for the time being and therefore decided to discontinue financing through these Stock Acquisition Rights.」
During the second quarter, 1,693,300 shares were issued through exercise of the Series 15 Stock Acquisition Rights, raising ¥360 million and bringing cumulative funds raised to ¥2,929 million. Against the original target of ¥5,390 million, the remaining 15,107 rights were acquired and cancelled on 19 October 2022, and additional financing through these Stock Acquisition Rights was discontinued. - FY2023-Q1AdvancedAnnual report
「Number of the relevant stock acquisition rights with exercise price adjustment provisions exercised during the quarter (units) 9,900 Number of shares delivered in connection with exercises during the quarter (shares) 990,000 Funds raised through exercises during the quarter (¥ million) 204 Cumulative number of the relevant stock acquisition rights with exercise price adjustment provisions as of the end of the quarter (units) 112,960 Cumulative number of shares delivered in connection with the relevant stock acquisition rights with exercise price adjustment provisions as of the end of the quarter (shares) 11,296,000 Cumulative funds raised through the relevant stock acquisition rights with exercise price adjustment provisions as of the end of the quarter (¥ million) 2,569」
During the first quarter, 9,900 Stock Acquisition Rights were exercised, resulting in the delivery of 990,000 shares and raising ¥204 million. Cumulative funds raised reached ¥2,569 million. - FY2022-Q3AdvancedAnnual report
「Number of the relevant stock acquisition rights with exercise price adjustment provisions exercised during the quarter (units) 71,870 Number of shares delivered in connection with exercises during the quarter (shares) 7,187,000 Funds raised through exercises during the quarter (¥ million) 1,545 Cumulative number of the relevant stock acquisition rights with exercise price adjustment provisions exercised as of the end of the quarter (units) 95,656 Cumulative number of shares delivered in connection with the relevant stock acquisition rights with exercise price adjustment provisions as of the end of the quarter (shares) 9,565,600 Cumulative funds raised through the relevant stock acquisition rights with exercise price adjustment provisions as of the end of the quarter (¥ million) 2,212」
With respect to the Series 15 Stock Acquisition Rights and other rights, 7,187,000 shares were issued and ¥1,545 million was raised during the third quarter. Cumulative funds raised reached ¥2,212 million, and cumulative shares delivered reached 9,565,600. - FY2022-Q2AdvancedAnnual report
「Funds generated from financing activities during the first six months of the current consolidated fiscal year amounted to ¥686 million (¥2 million in the same period of the previous year). This was mainly attributable to ¥668 million in proceeds from the issuance of shares through exercise of the Stock Acquisition Rights.」
During the second quarter, 20,970 Series 15 Stock Acquisition Rights were exercised, resulting in the delivery of 2,097,000 shares and raising ¥580 million. Cumulative totals were 2,378,600 shares and ¥666 million. - FY2022-Q1AdvancedAnnual report
「Number of the relevant stock acquisition rights with exercise price adjustment provisions exercised during the quarter (units): 2,816 Number of shares delivered in connection with exercises during the quarter (shares): 281,600 Funds raised through exercises during the quarter (¥ million): 86」
During the first quarter, 2,816 Series 15 Stock Acquisition Rights were exercised, resulting in the issuance of 281,600 shares and raising ¥86 million. - FY2021AdvancedAnnual report
「At a meeting of its Board of Directors held on 1 June 2021, the company resolved to issue the Series 15 Stock Acquisition Rights through a third-party allotment as set out below, and payment in full of the total issue price of the Stock Acquisition Rights was completed on 17 June 2021.」
As a subsequent event, the company disclosed the issuance and completed payment for 145,000 Series 15 Stock Acquisition Rights and specified a funding method expected to provide net proceeds of approximately ¥5,390 million. Uses of funds include ステムカイマル, iPS neural glial cells, a new iPS cell manufacturing business, new pipelines and working capital. - FY2021-Q2Update on financing through exercise of the Stock Acquisition RightsAnnual report
「Funds generated from financing activities during the first six months of the current consolidated fiscal year amounted to ¥2 million (¥6 million in the same period of the previous year). This was mainly attributable to ¥2 million in proceeds from the issuance of shares through exercise of the Stock Acquisition Rights.」
The company recorded ¥2 million in proceeds from the issuance of shares through exercise of the Stock Acquisition Rights, and equity financing continued. - FY2020AdvancedAnnual report
「Increase from the issuance of new shares through exercise of the Stock Acquisition Rights: 155,000 shares」
The company also issued 155,000 shares through exercise of the Stock Acquisition Rights during the period, and equity financing for research and development and other purposes continued. - FY2020-Q3AdvancedAnnual report
「Through the issuance of new shares upon exercise of the Stock Acquisition Rights and the issuance of new shares as restricted stock compensation, among other factors, the company’s share capital and capital surplus each increased by ¥48.567 million during the first nine months of the current consolidated fiscal year. As of the end of the third quarter, share capital was ¥6,767.487 million and capital surplus was ¥7,204.144 million.」
The issuance of new shares in connection with the exercise of the Stock Acquisition Rights and other transactions continued, increasing share capital and capital surplus by ¥48.567 million each during the first nine months of the current fiscal year. - FY2020-Q2AdvancedAnnual report
「Through the issuance of new shares upon exercise of the Stock Acquisition Rights, among other factors, the company’s share capital and capital surplus each increased by ¥17.228 million during the first six months of the current consolidated fiscal year. As of the end of the second quarter, share capital was ¥6,736.149 million and capital surplus was ¥7,172.806 million.」
The issuance of new shares upon exercise of the Stock Acquisition Rights increased share capital and capital surplus by ¥17.228 million each during the first six months of the current fiscal year, and equity financing continued. - FY2020-Q1AdvancedAnnual report
「Through the issuance of new shares upon exercise of the Stock Acquisition Rights, the company’s share capital and capital surplus each increased by ¥16.143 million during the first three months of the current consolidated fiscal year. As of the end of the first quarter, share capital was ¥6,735.064 million and capital surplus was ¥7,171.721 million.」
Exercise of the Stock Acquisition Rights increased share capital and capital surplus by ¥16.143 million each during the quarter, and equity financing for research and development and other purposes continued. - FY2019-Q3Cited as achievedAnnual report
「During the first nine months of the current consolidated fiscal year, the company issued the Series 14 Stock Acquisition Rights, with EVO FUND as the allottee, primarily to fund development expenses for iPS cell-derived neural glial cells (iGRP), a regenerative medicine product. The rights were fully exercised in August, raising ¥1,383 million.」
The company is reiterating that exercise of the Series 14 Stock Acquisition Rights was completed in August and that ¥1,383 million was raised for iGRP development. - FY2019-Q2AchievedAnnual report
「During the first six months of the current consolidated fiscal year, the company issued the Series 14 Stock Acquisition Rights, with EVO FUND as the allottee, primarily to fund development expenses for iPS cell-derived neural glial cells (iGRP), a regenerative medicine product. The rights were fully exercised in August, raising ¥1,383 million.」
Exercise of the Series 14 Stock Acquisition Rights, intended to fund iGRP development expenses, was completed in August, raising ¥1,383 million. - FY2019-Q1AdvancedAnnual report
「During the first quarter of the current consolidated fiscal year, the company resolved in May to issue the Series 14 Stock Acquisition Rights, with EVO FUND as the allottee, primarily to fund the development of iPS cell-derived neural glial cells (iGRP), a regenerative medicine product. The issuance is expected to raise approximately ¥2 billion.」
The company resolved to issue the Series 14 Stock Acquisition Rights, switched from the Series 12 Stock Acquisition Rights, with EVO FUND as the allottee, and specified plans to raise approximately ¥2 billion for iGRP development. - FY2018ReframedAnnual report
「① Research and development expenses for iPS cell therapies: ¥1,400 million; ② acquisition and setup costs for the Indian company made a subsidiary in April 2018: ¥400 million; ③ other research and development expenses: ¥247 million; total: ¥2,047 million」
After completing the exercise of the Series 12 Stock Acquisition Rights, the company indicated plans to switch its funding method to the Series 14 Stock Acquisition Rights issued through a third-party allotment and allocate a total of ¥2,047 million to iPS cell pharmaceuticals, its Indian subsidiary and other research and development. - FY2018-Q3AdvancedAnnual report
「Through the issuance of new shares upon the exercise of stock acquisition rights, our share capital and capital surplus each increased by ¥519.836 million during the third quarter of the current consolidated cumulative period. At the end of the third quarter of the current consolidated fiscal period, share capital was ¥6,010.164 million and capital surplus was ¥6,446.821 million.」
The issuance of new shares upon the exercise of stock acquisition rights increased share capital and capital surplus by ¥519.836 million each during the third quarter of the current consolidated cumulative period, advancing funding for cell therapy development and clinical trials. - FY2018-Q1AdvancedAnnual report
「Through the issuance of new shares upon the exercise of stock acquisition rights, our share capital and capital surplus each increased by ¥406.725 million during the first quarter of the current consolidated cumulative period. At the end of the first quarter of the current consolidated fiscal period, share capital was ¥5,897.052 million and capital surplus was ¥6,333.709 million.」
Exercise of stock acquisition rights increased share capital and capital surplus by ¥406.725 million each during the quarter, further advancing funding for development and clinical trials. - FY2017AdvancedAnnual report
「Funds obtained from financing activities during the consolidated fiscal year amounted to ¥1,127 million, compared with ¥1,700 million in the corresponding period of the previous year. This was mainly attributable to proceeds of ¥1,116 million from the issuance of shares upon the exercise of stock acquisition rights.」
Under the 12th Series of Stock Acquisition Rights, ¥1,116 million was raised during the fiscal year through exercises, and 3,535,500 new shares were issued. - FY2017-Q3First statedAnnual report
「We resolved to issue the 12th Series of Stock Acquisition Rights, with Merrill Lynch Japan Securities as the allottee, for the purpose of allocating the proceeds to expenses related to cell therapy development and clinical trials. We plan to raise approximately ¥2.6 billion through the issuance of these stock acquisition rights.」
The company planned to raise approximately ¥2.6 billion through the issuance of the 12th Series of Stock Acquisition Rights to Merrill Lynch Japan Securities, for cell therapy development and clinical trial expenses. The exercise period for the stock acquisition rights was from 20 December 2016 to 19 December 2017, and 220 rights were exercised during the third quarter, raising ¥84.480 million.